{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T17:36:08Z","timestamp":1791221768531,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T00:00:00Z","timestamp":1427673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.leukres.2015.03.016","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T21:49:20Z","timestamp":1428270560000},"page":"617-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine"],"prefix":"10.1016","volume":"39","author":[{"given":"M.","family":"Lazenby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zabkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2015.03.016_bib0215","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s12192-010-0211-0","article-title":"Increased expression of co-chaperone HOP with HSP90 and HSC70 and complex formation in human colonic carcinoma","volume":"15","author":"Kubota","year":"2010","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.leukres.2015.03.016_bib0220","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.tibs.2013.02.003","article-title":"The chaperone Hsp90: changing partners for demanding clients","volume":"38","author":"Rohl","year":"2013","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.leukres.2015.03.016_bib0225","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s12192-008-0035-3","article-title":"Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells","volume":"13","author":"Flandrin","year":"2008","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.leukres.2015.03.016_bib0230","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ctrv.2012.10.001","article-title":"Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions","volume":"39","author":"Hong","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.leukres.2015.03.016_bib0235","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/j.jprot.2011.12.028","article-title":"The network interaction of the human cytosolic 90kDa heat shock protein Hsp90: a target for cancer therapeutics","volume":"75","author":"da Silva","year":"2012","journal-title":"J Proteomics"},{"key":"10.1016\/j.leukres.2015.03.016_bib0240","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/sj.bjc.6605066","article-title":"Targeting HSP90 for cancer therapy","volume":"100","author":"Mahalingam","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.leukres.2015.03.016_bib0245","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nchembio.1212","article-title":"ATP-competitive inhibitors block protein kinase recruitment to the Hsp90\u2013Cdc37 system","volume":"9","author":"Polier","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.leukres.2015.03.016_bib0250","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1476-4598-9-77","article-title":"Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells","volume":"9","author":"Cheung","year":"2010","journal-title":"Mol Cancer"},{"key":"10.1016\/j.leukres.2015.03.016_bib0255","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1189\/jlb.0709502","article-title":"Differential heat shock protein localization in chronic lymphocytic leukemia","volume":"87","author":"Dempsey","year":"2010","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.leukres.2015.03.016_bib0260","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.yexcr.2012.05.012","article-title":"Heat shock proteins in hematopoietic malignancies","volume":"318","author":"Mjahed","year":"2012","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.leukres.2015.03.016_bib0265","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/ajh.23116","article-title":"Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment","volume":"87","author":"Fredly","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2015.03.016_bib0270","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.leukres.2005.02.010","article-title":"Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia","volume":"29","author":"Thomas","year":"2005","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2015.03.016_bib0275","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2008.12.002","article-title":"New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential","volume":"12","author":"Li","year":"2009","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.leukres.2015.03.016_bib0280","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1021\/jm980403y","article-title":"Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin","volume":"42","author":"Roe","year":"1999","journal-title":"J Med Chem"},{"key":"10.1016\/j.leukres.2015.03.016_bib0285","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/0008-5472.CAN-13-3263","article-title":"Ganetespib and HSP90: translating preclinical hypotheses into clinical promise","volume":"74","author":"Proia","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2015.03.016_bib0290","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1535-7163.MCT-11-0755","article-title":"Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy","volume":"11","author":"Ying","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.leukres.2015.03.016_bib0295","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-11-2967","article-title":"Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer","volume":"18","author":"Shimamura","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2015.03.016_bib0300","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/ijo.2012.1698","article-title":"Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression","volume":"42","author":"He","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.leukres.2015.03.016_bib0305","doi-asserted-by":"crossref","first-page":"e18552","DOI":"10.1371\/journal.pone.0018552","article-title":"Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK\/STAT signaling","volume":"6","author":"Proia","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.leukres.2015.03.016_bib0310","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s12272-012-1101-z","article-title":"Recent updates on the development of ganetespib as a Hsp90 inhibitor","volume":"35","author":"Choi","year":"2012","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.leukres.2015.03.016_bib0315","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-13-152","article-title":"A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies","volume":"13","author":"Goldman","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2015.03.016_bib0320","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1158\/1078-0432.CCR-12-3381","article-title":"A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer","volume":"19","author":"Socinski","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2015.03.016_bib0325","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose\u2013effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"10.1016\/j.leukres.2015.03.016_bib0330","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1182\/blood-2006-09-047217","article-title":"The role of PKC and PDK1 in monocyte lineage specification by Ras","volume":"109","author":"Pearn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.03.016_bib0335","doi-asserted-by":"crossref","first-page":"M111","DOI":"10.1074\/mcp.M111.014654","article-title":"Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response","volume":"11","author":"Sharma","year":"2012","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.leukres.2015.03.016_bib0340","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2004-04-1463","article-title":"Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells","volume":"105","author":"Frelin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.03.016_bib0345","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1158\/0008-5472.CAN-11-3600","article-title":"HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells","volume":"72","author":"Newman","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2015.03.016_bib0350","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2008-04-151928","article-title":"SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK","volume":"113","author":"Okawa","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.03.016_bib0355","doi-asserted-by":"crossref","first-page":"6831","DOI":"10.1158\/1078-0432.CCR-11-0821","article-title":"A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas","volume":"17","author":"Rajan","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2015.03.016_bib0360","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/bjh.12215","article-title":"The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells","volume":"161","author":"Walsby","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2015.03.016_bib0365","doi-asserted-by":"crossref","first-page":"e56134","DOI":"10.1371\/journal.pone.0056134","article-title":"Activity of the heat shock protein 90 inhibitor ganetespib in melanoma","volume":"8","author":"Wu","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.leukres.2015.03.016_bib0370","doi-asserted-by":"crossref","first-page":"e1595","DOI":"10.1038\/cddis.2014.555","article-title":"Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer","volume":"6","author":"Liu","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.leukres.2015.03.016_bib0375","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature01913","article-title":"A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors","volume":"425","author":"Kamal","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2015.03.016_bib0380","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/hon.805","article-title":"Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK\/Akt\/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors","volume":"25","author":"Siendones","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.leukres.2015.03.016_bib0385","doi-asserted-by":"crossref","first-page":"816","DOI":"10.18632\/oncotarget.991","article-title":"Targeting HSF1 sensitizes cancer cells to HSP90 inhibition","volume":"4","author":"Chen","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.leukres.2015.03.016_bib0390","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2010.168","article-title":"Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma","volume":"24","author":"Davenport","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.03.016_bib0395","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.leukres.2015.03.016_bib0400","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ccr.2008.08.002","article-title":"Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis","volume":"14","author":"Powers","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2015.03.016_bib0405","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00280-013-2134-9","article-title":"Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors","volume":"71","author":"Saif","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2015.03.016_bib0410","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1517\/13543784.2013.791280","article-title":"Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors","volume":"22","author":"Reikvam","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.leukres.2015.03.016_bib0415","doi-asserted-by":"crossref","first-page":"8803","DOI":"10.1074\/jbc.M111.320887","article-title":"Heat shock protein 90alpha (Hsp90alpha) is phosphorylated in response to DNA damage and accumulates in repair foci","volume":"287","author":"Quanz","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2015.03.016_bib0420","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nchembio.670","article-title":"Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90","volume":"7","author":"Moulick","year":"2011","journal-title":"Nat Chem Biol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615000879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615000879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T23:57:04Z","timestamp":1566518224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615000879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0145212615000879"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.03.016","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}